Differential Signaling Pathways in Medulloblastoma: Nano-biomedicine Targeting Non-coding Epigenetics to Improve Current and Future Therapeutics.

Daniil Sokolov Neha ShardaAindrila BanerjeeKseniia Denisenko Emad B Basalious Hem D Shukla Jaylyn Waddell Nadia M Hamdy Aditi Banerjee

Published in: Current pharmaceutical design (2024)

This review describes various MDB disease hallmarks, including the signaling mechanisms involved in pathophysiology, related-causal genes, epigenetics, downstream genes/epigenes, and possibly the causal disease genes/non-protein coding (nc)RNA/protein axis. Additionally, the challenges associated with MDB treatment are discussed, along with how they are being addressed using nano-technology and nano-biomedicine, with a listing of possible treatment options and future potential treatment modalities.

Keyphrases

genome wide
signaling pathway
current status
bioinformatics analysis
dna methylation
cancer therapy
epithelial mesenchymal transition
genome wide analysis
binding protein
risk assessment
induced apoptosis
endoplasmic reticulum stress